

METHODS IN MOLECULAR BIOLOGY

Series Editor

John M. Walker

School of Life and Medical Sciences

University of Hertfordshire

Hatfield, Hertfordshire, AL10 9AB, UK

For further volumes:

<http://www.springer.com/series/7651>

Rational Drug Design

Methods and Protocols

Edited by

Thomas Mavromoustakos and Tahsin F. Kellici

*Division of Organic Chemistry, Department of Chemistry, National and Kapodistrian University of Athens,
Panepistimiopolis, Zografou, Athens, Greece*

 **Humana Press**

Editors

Thomas Mavromoustakos
Division of Organic Chemistry
Department of Chemistry
National and Kapodistrian
University of Athens
Panepistimiopolis, Zografou
Athens, Greece

Tahsin F. Kellici
Division of Organic Chemistry
Department of Chemistry
National and Kapodistrian
University of Athens
Panepistimiopolis, Zografou
Athens, Greece

ISSN 1064-3745

ISSN 1940-6029 (electronic)

Methods in Molecular Biology

ISBN 978-1-4939-8629-3

ISBN 978-1-4939-8630-9 (eBook)

<https://doi.org/10.1007/978-1-4939-8630-9>

Library of Congress Control Number: 2018948185

© Springer Science+Business Media, LLC, part of Springer Nature 2018

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Printed on acid-free paper

This Humana Press imprint is published by the registered company Springer Science+Business Media, LLC part of Springer Nature.

The registered company address is: 233 Spring Street, New York, NY 10013, U.S.A.

Preface

*As you set out on the way to Ithaca
hope that the road is a long one,
filled with adventures, filled with discoveries.
The Laestrygonians and the Cyclopes,
Poseidon in his anger: do not fear them, ...
And if you find her poor, Ithaca didn't deceive you.
As wise as you will have become, with so much experience,
you will understand, by then, these Ithacas; what they mean.*

C. P. Cavafy

Translated by Daniel Mendelsohn

What excites us as guest editors in the rational drug design is the decision of beginning a trip toward Ithaca that can lead to the liberation from the thefts that steal our health. This trip that involves Laestrygonians and Cyclops is exciting and adventure. We do not mind if our Ithaca did not fill our expectations. We become mature and happy as we discover new avenues for reaching a new Ithaca. The rational drug design is an Odyssey that never ends and this is the essence of life.

This volume of *Methods in Molecular Biology* covers several aspects of rational drug design. Such aspects include (a) synthesis of novel bioactive drugs; (b) development and application of new methodologies to tackle problems related to discovery of potent molecules; (c) comprehend on concepts strictly related to the bioactivity, i.e., lipophilicity; (d) development and application of computational methods valuable toward the establishment of new approaches in the Ithaca trip of drug discovery; and (e) the effects of physicochemical and ADMET properties of the designed potential drugs.

Hereby is given an outline of the chapters covered in the volume. The first three chapters are dedicated to the design of peptides and peptidomimetics targeting the amyloid deposits and multiple sclerosis. Chapter 4 offers applications and comprehends on saturation transfer difference (STD) NMR in the mapping of the protein-ligand interface. In the fifth chapter the performance of docking tools is assessed. The use of structural biology in drug design is reviewed in the sixth chapter. Chapter 7 introduces new essential cheminformatic tools in ligand-based drug design. In Chapter 8 a thorough method of bioguided design of trypanosomicidal compounds is explained. The use of hybrid screening protocols is given in Chapter 9. Chapter 10 explains a novel method for the determination of unlabeled compound kinetics using the technique of time-resolved fluorescence resonance energy transfer. The new computational method of dynamic undocking is introduced in Chapter 11. The importance of lipophilicity in drug discovery is explained in Chapter 12. Chapters 13 and 14 explore the polypharmacology and the development of nuclear receptor modulators. An extensible orthogonal protocol that combines structure-based and ligand-based screening tools is introduced in Chapter 15. In Chapter 16 the synthesis of various adamantane derivatives with σ -receptor affinity is described. Examples of supervised molecular dynamics approaches are reviewed in Chapter 17. In Chapter 18 the synergistic action of biomolecular NMR methodologies is explained. Chapter 19 introduces the use of the dynamic and in silico pharmacophore approach in drug discovery. Chapters 20 and 21 deal with the rational design of inhibitors targeting MAGL and methyllysine reader protein spindlin1. The design

of natural product hybrids bearing triple antiplatelet profile is described in Chapter 22. Pharmacophore generation using phase is explained in Chapter 23. The design of inhibitors targeting histone deacetylases by filtering through ADMET, physicochemical and ligand-target flexibility properties is provided in Chapter 24. The occurrence of reactions in NMR tubes that may lead to new drug leads is explored in Chapter 25. The two last chapters deal with the angiotensin II type 1 receptor (AT1R). Chapter 26 provides the application of structure-based methods to develop new antagonists of the receptor, while Chapter 27 explores the importance homology modeling played in the case of AT1R.

This book, as can be understood from the analysis of its contents, was made possible through the generous contributions of many scientists, who shared their knowledge, for which we are very grateful. We are also sincerely grateful to the series editor, Professor John Walker, for his help, advice, and patient guidance in preparing this volume.

Athens, Greece

*Thomas Mavromoustakos
Tahsin F. Kellici*

Contents

<i>Preface</i>	<i>v</i>
<i>Contributors</i>	<i>xi</i>
1 Molecular Dynamics Simulations on the Bioactive Molecule of hIAPP22–29 (NFGAILSS) and Rational Drug Design	1
<i>Panagiotis Lagarias, Youness Elkhoul, Jayson Vedad, Athina Konstantinidi, Adam A. Profit, Tabsin F. Kellici, Antonios Kolocouris, Ruel Z. B. Desamero, and Thomas Mavromoustakos</i>	
2 Development of Peptide-Based Inhibitors of Amylin Aggregation Employing Aromatic and Electrostatic Repulsion	17
<i>Adam A. Profit and Ruel Z. B. Desamero</i>	
3 In Silico Drug Design: Non-peptide Mimetics for the Immunotherapy of Multiple Sclerosis	33
<i>Haralambos Tzoupis and Theodore Tselios</i>	
4 Binding Moiety Mapping by Saturation Transfer Difference NMR	49
<i>Jeffrey R. Brender, Janarthanan Krishnamoorthy, Anirban Ghosh, and Anirban Bhunia</i>	
5 Protein-Ligand Docking in Drug Design: Performance Assessment and Binding-Pose Selection	67
<i>Flavio Ballante</i>	
6 Rational Drug Design Using Integrative Structural Biology	89
<i>Magda S. Chegkazi, Michael Mamais, Anastasia I. Sotiropoulou, and Evangelia D. Chrysina</i>	
7 Enalos+ KNIME Nodes: New Cheminformatics Tools for Drug Discovery	113
<i>Dimitra-Danai Varsov, Spyridon Nikolakopoulos, Andreas Tsoumanis, Georgia Melagraki, and Antreas Afantitis</i>	
8 Bioguided Design of Trypanosomicidal Compounds: A Successful Strategy in Drug Discovery	139
<i>Guzmán Ignacio Álvarez Touron</i>	
9 A Hybrid Virtual Screening Protocol Based on Binding Mode Similarity	165
<i>Andrew Anighoro and Jürgen Bajorath</i>	
10 Single Step Determination of Unlabeled Compound Kinetics Using a Competition Association Binding Method Employing Time-Resolved FRET	177
<i>David A. Sykes and Steven J. Charlton</i>	
11 Dynamic Undocking: A Novel Method for Structure-Based Drug Discovery ...	195
<i>Maciej Majewski, Sergio Ruiz-Carmona, and Xavier Barril</i>	
12 The Impact of Lipophilicity in Drug Discovery: Rapid Measurements by Means of Reversed-Phase HPLC	217
<i>Constantinos Giaginis, Fotios Tsopeles, and Anna Tsantili-Kakoulidou</i>	

13	Exploring Polypharmacology in Drug Design	229
	<i>Patricia Saenz-Méndez and Leif A. Eriksson</i>	
14	Development of Nuclear Receptor Modulators	245
	<i>Simone Schierle and Daniel Merk</i>	
15	In Silico Screening of Compound Libraries Using a Consensus of Orthogonal Methodologies	261
	<i>Vassilios Myrianthopoulos, George Lambrinidis, and Emmanuel Mikros</i>	
16	Insights in Organometallic Synthesis of Various Adamantane Derivatives with Sigma Receptor-Binding Affinity and Antiproliferative/Anticancer Activity	279
	<i>Ioannis Papanastasiou</i>	
17	Supervised Molecular Dynamics (SuMD) Approaches in Drug Design	287
	<i>Davide Sabbadin, Veronica Salmaso, Mattia Sturlese, and Stefano Moro</i>	
18	Lead Identification Through the Synergistic Action of Biomolecular NMR and In Silico Methodologies	299
	<i>Konstantinos D. Marousis, Aikaterini C. Tsika, Maria Birkou, Minos-Timotheos Matsoukas, and Georgios A. Spyroulias</i>	
19	The Use of Dynamic Pharmacophore in Computer-Aided Hit Discovery: A Case Study	317
	<i>Ugo Perricone, Marcus Wieder, Thomas Seidel, Thierry Langer, and Alessandro Padova</i>	
20	Rational Development of MAGL Inhibitors	335
	<i>Carlotta Granchi, Flavio Rizzolio, Isabella Caligiuri, Marco Macchia, Adriano Martinelli, Filippo Minutolo, and Tiziano Tuccinardi</i>	
21	Application of Virtual Screening Approaches for the Identification of Small Molecule Inhibitors of the Methyllysine Reader Protein Spindlin1	347
	<i>Chiara Luise and Dina Robaa</i>	
22	Designing Natural Product Hybrids Bearing Triple Antiplatelet Profile and Evaluating Their Human Plasma Stability	371
	<i>Antonis Tsiailanis, Maria Tsoumani, Evgenios K. Stylos, Maria V. Chatziathanasiadou, Tahsin F. Kellici, Thomas Mavromoustakos, Alexandros D. Tselepis, and Andreas G. Tzakos</i>	
23	Pharmacophore Generation and 3D-QSAR Model Development Using PHASE	387
	<i>Eleni Vrontaki and Antonios Kolocouris</i>	
24	Design of Drugs by Filtering Through ADMET, Physicochemical and Ligand-Target Flexibility Properties	403
	<i>Marlet Martínez-Archundia, Martiniano Bello, and Jose Correa-Basurto</i>	
25	Reactions in NMR Tubes as Key Weapon in Rational Drug Design	417
	<i>Dimitrios Ntountaniotis</i>	

26 Application of Multiscale Simulation Tools on GPCRs. An Example
with Angiotensin II Type 1 Receptor 431
Ismail Erol, Busecan Aksoydan, Isik Kantarcioglu, and Serdar Durdagi

27 Angiotensin II Type 1 Receptor Homology Models: A Comparison
Between In Silico and the Crystal Structures 449
Tahsin F. Kellici

Index 461

Contributors

- ANTREAS AFANTITIS • *NovaMechanics Ltd., Nicosia, Cyprus*
- BUSECAN AKSOYDAN • *Department of Biophysics, Computational Biology and Molecular Simulations Laboratory, School of Medicine, Bahcesehir University, Istanbul, Turkey*
- GUZMÁN IGNACIO ÁLVAREZ TOURON • *Laboratorio de Moléculas Bioactivas, CENUR Litoral Norte, Universidad de la República, Paysandú, CP, Uruguay*
- ANDREW ANIGHORO • *Department of Life Science Informatics, B-IT, LIMES Program Unit Chemical Biology and Medicinal Chemistry, Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany*
- JÜRGEN BAJORATH • *Department of Life Science Informatics, B-IT, LIMES Program Unit Chemical Biology and Medicinal Chemistry, Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany*
- FLAVIO BALLANTE • *Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, Saint Louis, MO, USA; Department of Cell and Molecular Biology, Uppsala Biomedicinska Centrum BMC, Uppsala University, Uppsala, Sweden*
- XAVIER BARRIL • *Institut de Biomedicina de la Universitat de Barcelona (IBUB) and Facultat de Farmàcia, Universitat de Barcelona, Barcelona, Spain; Catalan Institution for Research and Advanced Studies (ICREA), Passeig Lluís Companys 23, Barcelona, Spain*
- MARTINIANO BELLO • *Laboratorio de Modelado Molecular, Bioinformática y Diseño de Fármacos, de la Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón s/n, Col. Casco de Santo Tomas, Delegación Miguel Hidalgo, C.P., Ciudad de México, Mexico*
- ANIRBAN BHUNIA • *Department of Biophysics, Bose Institute, Kolkata, India*
- MARIA BIRKOU • *Department of Pharmacy, University of Patras, Patras, Greece*
- JEFFREY R. BRENDER • *Radiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA*
- ISABELLA CALIGIURI • *Division of Experimental and Clinical Pharmacology, Department of Molecular Biology and Translational Research, National Cancer Institute and Center for Molecular Biomedicine, IRCCS, Pordenone, Italy*
- STEVEN J. CHARLTON • *School of Life Science, Queen's Medical Centre, University of Nottingham, Nottingham, UK*
- MARIA V. CHATZIATHANASIADOU • *Section of Organic Chemistry and Biochemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece*
- MAGDA S. CHEGKAZI • *Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, Athens, Greece; Faculty of Life Sciences and Medicine, Randall Centre for Cell and Molecular Biophysics, King's College London, London, UK*
- EVANGELIA D. CHRYSINA • *Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, Athens, Greece*
- JOSE CORREA-BASURTO • *Laboratorio de Modelado Molecular, Bioinformática y Diseño de Fármacos, de la Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón s/n, Col. Casco de Santo Tomas, Delegación Miguel Hidalgo, C.P., Ciudad de México, Mexico*

- RUEL Z. B. DESAMERO • *Department of Chemistry, York College and The Institute for Macromolecular Assemblies, Jamaica, NY, USA; Ph.D. Programs in Chemistry and Biochemistry, The Graduate Center of the City University of New York, New York, NY, USA*
- SERDAR DURDAGI • *Department of Biophysics, Computational Biology and Molecular Simulations Laboratory, School of Medicine, Bahcesehir University, Istanbul, Turkey*
- YOUNESS ELKHOUB • *Department of Chemistry, York College and The Institute for Macromolecular Assemblies, Jamaica, NY, USA; Ph.D. Programs in Chemistry and Biochemistry, The Graduate Center of the City University of New York, New York, NY, USA*
- LEIF A. ERIKSSON • *Department of Chemistry and Molecular Biology, University of Gothenburg, Gothenburg, Sweden*
- ISMAIL EROL • *Department of Biophysics, Computational Biology and Molecular Simulations Laboratory, School of Medicine, Bahcesehir University, Istanbul, Turkey*
- ANIRBAN GHOSH • *Department of Biophysics, Bose Institute, Kolkata, India*
- CONSTANTINOS GIAGINIS • *Department of Food Science and Nutrition, School of Environment, University of the Aegean, Myrina, Lemnos, Greece*
- CARLOTTA GRANCHI • *Department of Pharmacy, University of Pisa, Pisa, Italy*
- ISIK KANTARCIOGLU • *Department of Biophysics, Computational Biology and Molecular Simulations Laboratory, School of Medicine, Bahcesehir University, Istanbul, Turkey*
- TAHSIN F. KELLICI • *Division of Organic Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, Panepistimiopolis, Zografou, Athens, Greece*
- ANTONIOS KOLOCOURIS • *Department of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis, Zografou, Athens, Greece*
- ATHINA KONSTANTINIDI • *Department of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis, Zografou, Athens, Greece*
- JANARTHANAN KRISHNAMOORTHY • *Department of Biosciences, Jimma University, Jimma, ET, USA*
- PANAGIOTIS LAGARIAS • *Department of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis, Zografou, Athens, Greece*
- GEORGE LAMBRINIDIS • *Department of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis, Zografou, Athens, Greece*
- THIERRY LANGER • *Faculty of Life Sciences, Department of Pharmaceutical Chemistry, University of Vienna, Vienna, Austria*
- CHIARA LUISE • *Department of Pharmaceutical Chemistry, Martin-Luther University of Halle-Wittenberg, Halle/Saale, Germany*
- MARCO MACCHIA • *Department of Pharmacy, University of Pisa, Pisa, Italy*
- MACIEJ MAJEWSKI • *Institut de Biomedicina de la Universitat de Barcelona (IBUB) and Facultat de Farmàcia, Universitat de Barcelona, Barcelona, Spain*
- MICHAEL MAMAIS • *Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, Athens, Greece*
- KONSTANTINOS D. MAROUSIS • *Department of Pharmacy, University of Patras, Patras, Greece*
- ADRIANO MARTINELLI • *Department of Pharmacy, University of Pisa, Pisa, Italy*
- MARLET MARTÍNEZ-ARCHUNDIA • *Laboratorio de Modelado Molecular, Bioinformática y Diseño de Fármacos, de la Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón s/n, Col. Casco de Santo Tomas, Delegación Miguel Hidalgo, C.P., Ciudad de México, Mexico*

- MINOS-TIMOTHEOS MATSOUKAS • *Department of Pharmacy, University of Patras, Patras, Greece*
- THOMAS MAVROMOUSTAKOS • *Division of Organic Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, Panepistimiopolis, Zografou, Athens, Greece*
- GEORGIA MELAGRAKI • *NovaMechanics Ltd., Nicosia, Cyprus*
- DANIEL MERK • *Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Frankfurt, Germany*
- EMMANUEL MIKROS • *Department of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis Zografou, Athens, Greece; “Athena” Research and Innovation Center, Athens, Greece*
- FILIPPO MINUTOLO • *Department of Pharmacy, University of Pisa, Pisa, Italy*
- STEFANO MORO • *Molecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy*
- VASSILIOS MYRIANTHOPOULOS • *Department of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis Zografou, Athens, Greece; “Athena” Research and Innovation Center, Athens, Greece*
- SPYRIDON NIKOLAKOPOULOS • *NovaMechanics Ltd., Nicosia, Cyprus*
- DIMITRIOS NTOUNTANIOTIS • *Department of Chemistry, Laboratory of Organic Chemistry, National and Kapodistrian University of Athens, Athens, Greece*
- ALESSANDRO PADOVA • *Computer-Aided Drug Design Group, Fondazione Ri.MED, Palermo, Italy*
- IOANNIS PAPANASTASIOU • *School of Health Sciences, Department of Pharmacy, Division of Pharmaceutical Chemistry, National and Kapodistrian University of Athens, Panepistimiopolis—Zografou, Athens, Greece*
- UGO PERRICONE • *Computer-Aided Drug Design Group, Fondazione Ri.MED, Palermo, Italy*
- ADAM A. PROFIT • *Department of Chemistry, York College and The Institute for Macromolecular Assemblies, Jamaica, NY, USA; Ph.D. Programs in Chemistry and Biochemistry, The Graduate Center of the City University of New York, New York, NY, USA*
- FLAVIO RIZZOLIO • *Division of Experimental and Clinical Pharmacology, Department of Molecular Biology and Translational Research, National Cancer Institute and Center for Molecular Biomedicine, IRCCS, Pordenone, Italy; Department of Molecular Science and Nanosystems, Ca’ Foscari Università di Venezia, Venezia-Mestre, Italy*
- DINA ROBAA • *Department of Pharmaceutical Chemistry, Martin-Luther University of Halle-Wittenberg, Halle/Saale, Germany*
- SERGIO RUIZ-CARMONA • *Institut de Biomedicina de la Universitat de Barcelona (IBUB) and Facultat de Farmàcia, Universitat de Barcelona, Barcelona, Spain*
- DAVIDE SABBADIN • *Syngenta Crop Protection AG, Stein, Switzerland*
- PATRICIA SAENZ-MÉNDEZ • *Department of Chemistry and Molecular Biology, University of Gothenburg, Gothenburg, Sweden; Computational Chemistry and Biology Group, Facultad de Química, UdelaR, Montevideo, Uruguay*
- VERONICA SALMASO • *Molecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy*
- SIMONE SCHIERLE • *Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Frankfurt, Germany*

- THOMAS SEIDEL • *Faculty of Life Sciences, Department of Pharmaceutical Chemistry, University of Vienna, Vienna, Austria*
- ANASTASIA I. SOTIROPOULOU • *Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, Athens, Greece*
- GEORGIOS A. SPYROULIAS • *Department of Pharmacy, University of Patras, Patras, Greece*
- MATTIA STURLESE • *Molecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy*
- EVGENIOS K. STYLOS • *Section of Organic Chemistry and Biochemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece; Biotechnology Laboratory, Department of Biological Applications and Technology, University of Ioannina, Ioannina, Greece*
- DAVID A. SYKES • *School of Life Science, Queen's Medical Centre, University of Nottingham, Nottingham, UK*
- ANNA TSANTILI-KAKOULIDOU • *Department of Pharmaceutical Chemistry, Faculty of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis, Zografou, Athens, Greece*
- ALEXANDROS D. TSELEPIS • *Atherothrombosis Research Centre/Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece*
- THEODORE TSELIOS • *Department of Chemistry, University of Patras, Patras, Greece*
- ANTONIS TSIAILANIS • *Section of Organic Chemistry and Biochemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece*
- AIKATERINI C. TSIKA • *Department of Pharmacy, University of Patras, Patras, Greece*
- FOTIOS TSOPELAS • *Laboratory of Inorganic and Analytical Chemistry, School of Chemical Engineering, National Technical University of Athens, Athens, Greece*
- MARIA TSOUMANI • *Atherothrombosis Research Centre/Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece*
- ANDREAS TSOUMANIS • *NovaMechanics Ltd., Nicosia, Cyprus*
- TIZIANO TUCCINARDI • *Department of Pharmacy, University of Pisa, Pisa, Italy*
- ANDREAS G. TZAKOS • *Section of Organic Chemistry and Biochemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece*
- HARALAMBOS TZOUPIS • *Department of Chemistry, University of Patras, Patras, Greece*
- DIMITRA-DANAI VARSOU • *NovaMechanics Ltd., Nicosia, Cyprus*
- JAYSON VEDAD • *Department of Chemistry, York College and The Institute for Macromolecular Assemblies, Jamaica, NY, USA; Ph.D. Programs in Chemistry and Biochemistry, The Graduate Center of the City University of New York, New York, NY, USA*
- ELENI VRONTAKI • *Department of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis Zografou, Athens, Greece*
- MARCUS WIEDER • *Faculty of Life Sciences, Department of Pharmaceutical Chemistry, University of Vienna, Vienna, Austria; Faculty of Chemistry, Department of Computational Biological Chemistry, University of Vienna, Vienna, Austria*